Price List - Jideytro - Lung Cancer - NA.xlsx
XLSX spreadsheet 44 KB Posted
- Solicitation number
- HT9402-26-Q-9403
- Issued by
-
Defense Health Agency
About this file
This is a pricing template for a Department of War (DoW) Uniform Formulary Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for lung cancer pharmaceutical agents. The document is structured as a template with pricing appendices for ten newly approved drugs in the lung cancer therapeutic class, all scheduled for review at the November 4-5, 2026 P&T Committee meeting. Manufacturers are required to submit quotes by September 24, 2026, and must include a completed Quote Review Checklist and fully executed signature pages. The pricing template accommodates multiple formulary scenarios, including Uniform Formulary (with both Military Treatment Facility & Mail Order and Tier 2/Tier 3 classifications) and Non-Formulary categories, with separate sections for Blanket Purchase Agreement pricing (price per NDC package size and price per unit) and Additional Discount Program pricing using either non-FAMP (Federal Ceiling Price) or WAC (Wholesale Acquisition Cost) discount methodologies. The template specifies that pricing per unit of measure must be uniform across all available package sizes within each dispensing venue and notes that agents without submitted or selected quotes may be designated as non-step preferred (after-step) therapy.
The document emphasizes that the P&T Committee may recommend preferential tier classification for non-generic agents or complete exclusion from the TRICARE pharmacy benefit program based on comparative clinical and cost effectiveness. Prior Authorization may apply to selected agents. All pricing information is subject to confidentiality restrictions as noted in the quote. This template applies to the DoW's requirement under 10 U.S.C. 1074g and 32 CFR 199.21 to establish an effective and efficient pharmacy benefits program for the Military Health System, with the Defense Health Agency authorized to award resulting BPA and ADP agreements based on the P&T Committee recommendations.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Formulary Placement of FDA NADs.pdf | ||
| RFQ HT9402-26-Q-9403 NAD.pdf | ||
| Price List - Furoscix ReadyFlow - Diuretics - NA.xlsx | XLSX spreadsheet | |
| Price List - Zenbexus - Multiple Myeloma - NA.xlsx | XLSX spreadsheet | |
| Price List - Omlyclo - Atopy - NA.xlsx | XLSX spreadsheet | |
| Price List - Gywn Lo - Contraceptive Agents - Misc.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - RizaFilm - Migraine Agents - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 271LCNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 271LCNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | LUNG CANCER | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 271LCNAG1T21M | Tier 2 | 1 or more | |
| 271LCNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .